Status:
COMPLETED
InO - A Retrospective Study of UK Patients With Leukaemia
Lead Sponsor:
Pfizer
Conditions:
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to describe the demographics and clinical characteristics, treatment pathway, and effectiveness and safety of inotuzumab ozogamicin in patients with relapsed/refractory B-...
Eligibility Criteria
Inclusion
- Patients with relapsed/refractory ALL.
- Patients who initiated InO between 1st of June 2016 and date of data collection.
- Patients who accessed InO treatment via NHS commissioning, via the CUP, or via private purchase.
- Patient aged ≥18 years old at initiation of InO treatment
Exclusion
- Patients initiated on treatment with InO at a different hospital than the ones selected in this study.
- Patients with \<3 months of follow-up since index date, unless death occurs \<3 months from index date.
Key Trial Info
Start Date :
January 6 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 27 2021
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT04456959
Start Date
January 6 2020
End Date
January 27 2021
Last Update
September 28 2022
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Bristol NHS Foundation Trust
Bristol, United Kingdom, BS1 3NU
2
University College London Hospital NHS Foundation Trust
London, United Kingdom, NW1 2PG
3
The Royal Marsden NHS Foundation Trust of Fulham Road
London, United Kingdom, SW3 6JJ
4
Taunton and Somerset NHS Foundation Trust of Musgrove Park Hospital
Taunton, United Kingdom, TA1 5DA